Login

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ('Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant. The shares of common stock were sold at a public offering price of $6.00 per share and the pre-funded warrants were sold at a public offering price of $5.99999 per share. The gross proceeds to Aura from the offering were approximately $299.4 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities sold in the offering were offered by Aura.